I give Niagen Bioscience, Inc. a hold rating. The company has a cash-rich balance sheet with no debt and high-quality earnings. Shareholders have already faced 47.5% dilution since 2016, and there ...
Arcus Biosciences (RCUS): Losses Widen 26% Annually, Revenue Growth Projections Test Bullish Outlook
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The analyst notes that Tuhura Biosciences, Inc.’s revolving credit facility with Parkview Holdings One, LLC, secured by substantially all of its assets and bearing a 12% interest rate, introduces ...
TuHURA Biosciences remains a high-risk investment due to severe cash constraints and imminent dilution risk despite progress in its immunotherapy pipeline. HURA's phase 3 trial for IFx-Hu2.0 in ...
Investing.com - H.C. Wainwright lowered its price target on Lexaria Bioscience (NASDAQ:LEXX) to $4.00 from $5.00 on Tuesday, while maintaining a Buy rating on the stock. Currently trading at $0.90, ...
Detailed price information for Dare Bioscience Inc (DARE-Q) from The Globe and Mail including charting and trades.
In early May 2026, Pulse Biosciences reported a wider first-quarter net loss of US$18.58 million and basic loss per share of US$0.27, while highlighting strong European feasibility data for its nPulse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results